Table 2.
Partial name | Clinical use or characteristic | |
---|---|---|
Beginning of name | Chosen by manufacturer | |
Middle of name |
-lim -cir -tu |
-Immune/inflammatory -Cardiac disorder -Tumor or neoplasm |
End of name |
-ximab -zumab -umab |
Chimeric (murine variable region plus human Fc) Humanized (murine complementarity determining region) Human |